Table 3.
Risk of cardiovascular disease in the two drug groups after propensity score matching between 2016 and 2018
| Classification | Febuxostat (26,962 patients) | Allopurinol (26,962 patients) | Crude HR (95% CI) | Adjusted HR** (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| Number of patients (n) |
Person–years | Incidence rate (1,000 person–years) | Number of patients (n) | Person–years | Incidence rate (1,000 person–years) | |||
| Primary outcome variable* | ||||||||
| Cardiovascular disease | 3127 | 20,343.7 | 153.7 | 3,039 | 24,108.4 | 126.1 | 1.09 (1.04–1.15) | 1.04 (0.99–1.10) |
| Secondary outcome variable | ||||||||
| Myocardial infarction | 197 | 22,689.9 | 8.7 | 219 | 26,634.7 | 8.2 | 0.98 (0.81–1.18) | 0.88 (0.71–1.08) |
| Ischemic heart disease | 727 | 22,251.4 | 32.7 | 745 | 26,190.9 | 28.4 | 1.05 (0.95–1.17) | 0.98 (0.88–1.10) |
| Stroke | 1100 | 21,951.6 | 50.1 | 1,098 | 25,811.0 | 42.5 | 1.06 (0.97–1.15) | 1.01 (0.92–1.10) |
| Transient ischemic attack | 235 | 22,657.8 | 10.4 | 219 | 26,630.7 | 8.2 | 1.16 (0.97–1.40) | 1.10 (0.90–1.35) |
| Heart failure | 1303 | 21,839.4 | 59.7 | 1,315 | 25,698.2 | 51.2 | 1.07 (0.99–1.15) | 0.99 (0.91–1.08) |
| Coronary revascularization (treatment) | 70 | 22,792.1 | 3.1 | 73 | 26,766.1 | 2.7 | 1.09 (0.76–1.56) | 0.98 (0.64–1.49) |
| All-cause death | 7 | 20,343.7 | 0.3 | 8 | 24,108.4 | 0.3 | 1.07 (0.39–2.96) | 1.38 (0.37–5.16) |
*All-cause death: includes 7 and 8 patients in the febuxostat and allopurinol groups, respectively
Coronary revascularization is a treatment code that has secondary outcome variables and overlapping values
**Covariate correction: the history of cardiovascular disease before the index date
Average follow-up of 276 and 327 days in the febuxostat and allopurinol groups, respectively